iQ-007 Considered as First-in-Class Therapeutic Agent in Prestigious Journal of Medicinal Chemistry

International team of scientists share research that demonstrates the effectiveness of iQ-007 and its unique mechanism of action

Discovery of iQ-007 [(R)-AS-1], a Novel Orally Bioavailable EAAT2 Modulator with Drug-like Properties

Princeton, NJ, September 8, 2022 ─ iQure Pharma Inc. (iQure), a Princeton-based global biotech company, has announced that research into one of its lead drug candidates, iQ-007 ((R)-AS-1), has been published in the Journal of Medicinal Chemistry, a peer-reviewed journal, published by the American Chemical Society. The research, Discovery of (R)-N-Benzyl-2-(2,5-dioxopyrrolidin-1-yl)propanamide [(R)-AS-1], a Novel Orally Bioavailable EAAT2 Modulator with Drug-like Properties and Potent Antiseizure Activity In Vivo discusses iQ-007’s unique mechanism of action and suggests iQ-007 as a First-in-Class EAAT2 Positive Allosteric Modulator (PAM).

The research manuscript is co-authored by an international team of researchers, including Andréia C. K. Fontana, (Drexel University, Philadelphia, US), Christa E. Müller (Bonn University, DE), Ivet Bahar (University of Pittsburgh, US), R. Kaminski and K. Kaminski (Jagiellonian University, PL).

“This publication is a milestone event for iQ-007, confirming its unique mechanism of action and its potential as a new therapeutic,” said iQure R&D Director, Henk de Wilde. “Our internal efficacy data in neuropathic pain and the epilepsy data discussed in this paper, confirm iQ-007’s potential as a First-in-Class therapeutic candidate for more than one indication. We are now progressing with development of iQ-007 towards IND and subsequent clinical testing.”

“The iQure team would like to thank all researchers for their respective contributions to the publication,” added Henk de Wilde. “This international effort, further supported by iQ-007 participation in the NIH ETSP program, helps to translate this exciting discovery into a new therapy, helping patients in urgent need of novel, effective and safe, pain and epilepsy treatments.”

About Chronic Pain

Chronic pain is one of the most common chronic conditions in the United States. In 2019, 20.4% of adults experienced chronic pain and 7.4% had high-impact chronic pain that severely limited daily life or work activities. An estimated twenty million Americans experience some form of peripheral neuropathy, one of the most severe forms of chronic pain.

About Epilepsy

Epilepsy affects nearly 50 million people worldwide, making it one of the most common neurological diseases globally, according to WHO. Progress in epilepsy research has led to the approval and marketing authorization of more than 30 antiseizure drugs (ASDs) over recent decades. Yet, despite this unquestionable therapeutic success, approximately one-third of epilepsy patients still experience uncontrolled and debilitating seizures. Epilepsy, and especially drug-resistant epilepsy, remains an unmet clinical need affecting as many as 20%-40% of the epileptic population, corresponding to more than 400,000 patients in the US alone.

About iQure Pharma

A global biotech firm headquartered in Princeton, New Jersey, iQure Pharma is focused on the development of new therapeutics for CNS, including neuropathic pain, epilepsy and other neurodegenerative diseases. iQure researchers, clinicians, and pharmaceutical professionals work closely with academic partners, industry experts, and patient organizations to build medically and socially beneficial therapies. For more information about supporting iQure initiatives, contact iQure CFO Dr. Anna Rzewuska at anna.rzewuska@iqurepharma.com.

iQure Pharma Secures $600K in Commitments in Early Closing to Research Neuropathic Pain Therapies

Keiretsu Forum and Business Angel Investors Provide Funding to Support Research into Neuropathic Pain Compounds iQ-007 and iQ-008

Princeton, NJ, August 31, 2022 ─ iQure Pharma Inc. (iQure), a Princeton-based global biotech company, today confirmed completion of Early Closing as part of its Series A investment, which will support ongoing research into non-opioid therapeutics for neuropathic pain.

iQure Pharma has secured over $600k of commitments to date and is supported by Keiretsu Mid-Atlantic, together with business angels associated with Keiretsu’s Accelerator Fund and Keiretsu Northwest, to advance the preclinical development of iQure’s novel therapeutics, iQ-007 and iQ-008. In addition, both compounds are supported by non-dilutive funding through the NIH epilepsy (ETSP) and NIH pain (PSPP) programs.

“We are so thankful to all of our early investors,” said iQure Chief Executive Officer Pawel Zolnierczyk. “Their support of our novel therapeutics for neuropathic pain, validates our strong experimental data. Along with support from the NIH, this latest investment enables iQure to further develop our assets and increase our value. With the support of our investors and researchers, we are proud to be a part of the biotech community developing promising therapies of the future.”

iQ-007 has demonstrated positive results, including NIH ETSP tests, which show that the compound has the ability to treat pain, epilepsy and other potentially neurodegenerative diseases. iQ-008, a novel analgesic compound, has achieved significant progress within the NIH PSPP program, and is advancing to the next stage in the Preclinical Screening Platform for Pain (PSPP), under the NIH HEAL Initiative, a program designed to facilitate the identification of potential non-addictive treatments for acute and chronic pain conditions and alternatives to opioid analgesics.

Chronic pain is one of the most common chronic conditions in the United States. In 2019, 20.4% of adults experienced chronic pain and 7.4% had high-impact chronic pain that severely limited daily life or work activities. An estimated twenty million Americans experience some sort of peripheral neuropathy, one of the most severe forms of chronic pain.

About iQure Pharma

A global biotech firm headquartered in Princeton, New Jersey, iQure Pharma is focused on the development of new therapeutics for neuropathic pain, epilepsy and wide-ranging neurodegenerative diseases. iQure researchers, clinicians, and pharmaceutical professionals work closely with academic partners, industry experts, and patient organizations to build medically and socially beneficial therapies. For more information about supporting iQure’s initiatives, contact iQure CFO Dr. Anna Rzewuska at anna.rzewuska@iqurepharma.com.

iQure Pharma’s Lead Therapeutic Advances in the NIH Preclinical Screening Platform for Pain (PSPP)

iQ-008 is a novel analgesic being investigated as a non-addictive therapeutic for neuropathic pain

Princeton, New Jersey, July 1, 2022 - iQure Pharma Inc. (iQure), a US-based global biotech company, confirms that its lead asset, iQ-008, a novel analgesic compound, is progressing to the next stage in the Preclinical Screening Platform for Pain (PSPP) as part of the National Institutes of Health (NIH) HEAL Initiative (Helping to End Addiction Long-term).

The PSPP program offers testing that includes an assessment of in vitro and pharmacokinetic and side effect profiles, abuse liability, and efficacy in models relevant to human pain conditions.

“This is very good news and an important step in the development of iQ-008 as a promising therapeutic,” said iQure Chief Executive Officer Pawel Zolnierczyk. “With this ongoing support from NIH, we will be able to further our understanding of iQ-008’s profile, which will contribute to the progression of iQ-008 as an Investigational New Drug (IND).”

iQure researchers developed iQ-008 as a therapeutic for neuropathic pain, in response to the more than 25 million Americans who live with chronic pain and are forced to rely solely on potentially addictive opioid medications for pain management.

About iQure Pharma

A global biotech firm headquartered in Princeton, New Jersey, iQure Pharma is focused on the development of new therapeutics for neuropathic pain. iQure researchers, clinicians, and pharmaceutical professionals work closely with academic partners, industry experts, and patient organizations to build medically and socially beneficial therapies. For more information about supporting iQure’s initiatives, contact iQure CFO Dr. Anna Rzewuska at anna.rzewuska@iqurepharma.com.